Bosentan is superior to ambrisentan in reducing the expression of asthma- and COPD-related cytokines

J. Knobloch, Y. Lin, D. Jungck, K. Urban, J. Strauch, E. Stoelben, J. Behr, A. Koch (Bochum, Cologne, Germany)

Source: Annual Congress 2011 - Translational models of disease
Session: Translational models of disease
Session type: Thematic Poster Session
Number: 847
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Knobloch, Y. Lin, D. Jungck, K. Urban, J. Strauch, E. Stoelben, J. Behr, A. Koch (Bochum, Cologne, Germany). Bosentan is superior to ambrisentan in reducing the expression of asthma- and COPD-related cytokines. Eur Respir J 2011; 38: Suppl. 55, 847

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD
Source: Eur Respir J 2009; 33: 778-784
Year: 2009



Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients
Source: Annual Congress 2009 - New drugs for airways disease
Year: 2009

Addition of leukotriene antagonists or long-acting β2-agonists to inhaled corticosteroid therapy in asthma treatment increases drug costs without decreasing service-related costs
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

The influence of β2 adrenoceptor polymorphisms on the response to formoterol, montelukast or higher dose budesonide in patients with uncontrolled asthma despite low dose budesonide
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004


Comparison of the effectiveness of azithromycin and budesonide versus theophylline and budesonide in the suppression of pro-inflammatory cytokines in patients with COPD
Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases
Year: 2020


Low-dose inhaled glucocorticoids are more effective tham LTRA in improving functional data in asthmatics
Source: Eur Respir J 2004; 24: Suppl. 48, 126s
Year: 2004

Irisin is associated with clinical outcomes and up-regulated by long-acting anticholinergics in COPD
Source: International Congress 2017 – Therapeutic approaches in lung disease
Year: 2017

Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


The direct costs of exacerbations in COPD and the effect of cilomilast treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002

Complementary effects on IL-1, IL-6, TNF-alpha of salmeterol and/or montelukast added to fluticasone in moderate asthmatics
Source: Eur Respir J 2004; 24: Suppl. 48, 580s
Year: 2004

Salmeterol treatment improves corticosteroid responsivness in patients with corticosteroid-insensitive severe asthma
Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population
Year: 2005


Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Tiotropium enhances the inhibitory effect of the long acting β2-agonist olodaterol on the release of IL-6 and IL8 by primary human lung fibroblasts of asthma patients
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
Source: Eur Respir J 2012; 40: 1106-1114
Year: 2012



The therapeutic effects of zafirlukast on COPD induced pulmonary hypertension
Source: Eur Respir J 2001; 18: Suppl. 33, 415s
Year: 2001

Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016


The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Formoterol is more effective than salmeterol in suppressing neutrophil reactivity
Source: ERJ Open Res 2015
Year: 2015


Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013


Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011